Agree there is lots of competition in the field (I work in the field with a lot of early stage radiopharmaceutical biotechs, Australian and International) - but not many companies have the same level of quality (using FDA Fast Track designations as a metric) or maturity (using current number of phase II or III trials as a metric). Clarity are years ahead of most of the competition (even if a few years behind Telix).
CU6 Price at posting:
$3.46 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)